Charles River Opens New Viral Clearance Facility in Germany
January 10, 2011 - Charles River Biopharmaceutical Services (BPS) is pleased to announce that it has updated and expanded its Cologne, Germany-based viral clearance operation by moving it to a new state-of-the-art facility within Cologne. This move enables clients to take advantage of an expanded capacity, as well as more capabilities to support their viral clearance studies.
This new BPS facility has the ability to handle up to five studies in parallel, which means more flexibility and improved timelines for clients, all while providing a more comfortable working environment. The new space also features an improved “zone” configuration, enabling a clearer, leaner workflow that further ensures contamination avoidance and Good Laboratory Practice (GLP) compliance, as well as maximizing worker safety.
Finally, with more space, we have been able to implement even more cutting-edge instrumentation, as well as update our existing technologies, including chromatography and advanced filtration and cooling equipment, in addition to an electronic access system.
The new facility is currently up and running and ready to provide the customized support you can rely on to help you design and perform successful viral clearance studies under strict regulatory guidelines.
Charles River will be hosting the official grand opening ceremony at the facility on February 17-18, 2011. The two-day event will include a welcome reception, tour, scientific presentations and opportunities to interact with our expert staff. To register to attend, please visit the event website.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 27–May 29
Charles River and the René Remie Surgical Skills Centre (RRSSC) have joined their expertise and are pleased to offer a 3-day surgery training course. Held at the RRSSC in the Netherlands, this training is designed to be very practical and combines lectures with hands-on exercises, ensuring you receive the most comprehensive training experience. This course is recommended for simple procedures only (e.g., simple exeresis, simple catheterizations such as jugular vein or femoral vein, simple ALZET pump implantation, ECG radiotelemetry).
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.